Literature DB >> 22178383

Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold.

Patricia Galán-Malo1, Laura Vela, Oscar Gonzalo, Rubén Calvo-Sanjuán, Lucía Gracia-Fleta, Javier Naval, Isabel Marzo.   

Abstract

Microtubule poisons and other anti-mitotic drugs induce tumor death but the molecular events linking mitotic arrest to cell death are still not fully understood. We have analyzed cell fate after mitotic arrest produced by the microtubule-destabilizing drug vincristine in a panel of human tumor cell lines showing different response to vincristine. In Jurkat, RPMI 8226 and HeLa cells, apoptosis was triggered shortly after vincristine-induced mitotic arrest. However, A549 cells, which express a great amount of Bcl-x(L) and undetectable amounts of Bak, underwent mitotic slippage prior to cell death. However, when Bcl-x(L) gene was silenced in A549 cells, vincristine induced apoptosis during mitotic arrest. Another different behavior was found in MiaPaca2 cells, where vincristine caused death by mitotic catastrophe that switched to apoptosis when cyclin B1 degradation was prevented by proteasome inhibition. Overexpression of Bcl-x(L) or silencing Bax and Bak expression delayed the onset of apoptosis in Jurkat and RPMI 8226 cells, enabling mitotic slippage and endoreduplication. In HeLa cells, overexpression of Bcl-x(L) switched cell death from apoptosis to mitotic catastrophe. Mcl-1 offered limited protection to vincristine-induced cell death and Mcl-1 degradation was not essential for vincristine-induced death. All these results, taken together, indicate that the Bcl-x(L)/Bak ratio and the ability to degrade cyclin B1 determine cell fate after mitotic arrest in the different tumor cell types.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178383     DOI: 10.1016/j.taap.2011.11.021

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A.

Authors:  Ariane Chan; Connie Gilfillan; Nikki Templeton; Ian Paterson; Peter T Northcote; John H Miller
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

2.  6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.

Authors:  Shengnan Du; Jeffrey G Sarver; Christopher J Trabbic; Paul W Erhardt; Allen Schroering; William A Maltese
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-13       Impact factor: 3.333

3.  Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma.

Authors:  Aaron P Havas; Kameron B Rodrigues; Anvi Bhakta; Joseph A Demirjian; Seongmin Hahn; Jack Tran; Margarethakay Scavello; Ana A Tula-Sanchez; Yi Zeng; Monika Schmelz; Catharine L Smith
Journal:  Cancer Biol Ther       Date:  2016-10-28       Impact factor: 4.742

4.  A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies.

Authors:  Ting Zhang; Yong Zheng; Qiang Peng; Xi Cao; Tao Gong; Zhirong Zhang
Journal:  Int J Nanomedicine       Date:  2013-03-20

5.  Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells.

Authors:  Hongxin Shen; Sanjun Shi; Zhirong Zhang; Tao Gong; Xun Sun
Journal:  Theranostics       Date:  2015-04-05       Impact factor: 11.556

6.  Synthesis and biological evaluation of indolyl-pyridinyl-propenones having either methuosis or microtubule disruption activity.

Authors:  Christopher J Trabbic; Jean H Overmeyer; Evan M Alexander; Emily J Crissman; Heather M Kvale; Marcie A Smith; Paul W Erhardt; William A Maltese
Journal:  J Med Chem       Date:  2015-02-19       Impact factor: 7.446

7.  Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.

Authors:  Karuna Mittal; Shashi Donthamsetty; Ramneet Kaur; Chunhua Yang; Meenakshi V Gupta; Michelle D Reid; Da Hoon Choi; Padmashree C G Rida; Ritu Aneja
Journal:  Br J Cancer       Date:  2017-03-23       Impact factor: 7.640

8.  Universal response in the RKO colon cancer cell line to distinct antimitotic therapies.

Authors:  Alexander Lorz; Dana-Adriana Botesteanu; Doron Levy
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.